Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

[1]  S. Hammer,et al.  Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. , 2001, JAMA.

[2]  K. Brinkman,et al.  Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. , 2001, AIDS.

[3]  S. Knowles,et al.  Idiosyncratic drug reactions: the reactive metabolite syndromes , 2000, The Lancet.

[4]  D. Vittecoq,et al.  Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. , 1999, AIDS.

[5]  J. Uetrecht,et al.  New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.

[6]  J. Morgan,et al.  Acute Hypersensitivity with Delavirdine , 1999, Antiviral therapy.

[7]  T. Harrer,et al.  A dose‐ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment‐naive subjects , 1998, AIDS.

[8]  B. Hoen,et al.  DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Schooley,et al.  Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV‐infected adults , 1998, AIDS.

[10]  M Pirmohamed,et al.  Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. , 1998, Chemical research in toxicology.

[11]  A. Barner,et al.  Nevirapine and rashes , 1998, The Lancet.

[12]  J. Dieleman,et al.  Acute respiratory failure associated with the human immunodeficiency virus (HIV) protease inhibitor indinavir in an HIV-infected patient. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Boxwell,et al.  Nevirapine-associated Stevens-Johnson syndrome , 1998, The Lancet.

[14]  J. Kooman,et al.  Severe allergic reaction after repeated exposure to indinavir. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R D deShazo,et al.  Allergic reactions to drugs and biologic agents. , 1997, JAMA.

[16]  Wouter J. Rietsema.  Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  P. Bonfanti,et al.  Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. , 1997, AIDS.

[18]  N. Shear,et al.  Mechanisms of drug reactions: the metabolic track. , 1996, Seminars in cutaneous medicine and surgery.

[19]  D. Cooper,et al.  A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients , 1996, AIDS.

[20]  J. Roujeau,et al.  Hypersensitivity syndrome associated with zalcitabine therapy , 1996, The Lancet.

[21]  M. Wassef,et al.  Hypersensitivity of zidovudine: report of a case of anaphylaxis and review of the literature. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  T. Vree,et al.  Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? , 1995, AIDS.

[23]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[24]  Andrew Carr,et al.  Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). , 1993, The Journal of allergy and clinical immunology.

[25]  S. Broder,et al.  Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection. , 1989, Journal of the American Academy of Dermatology.

[26]  N. Pedersen,et al.  Feline immunodeficiency virus infection. , 1989, Veterinary immunology and immunopathology.

[27]  N. Adkinson.  Risk factors for drug allergy. , 1984, The Journal of allergy and clinical immunology.

[28]  R. Nelson,et al.  A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. , 2001, Pediatrics.

[29]  P. Easterbrook,et al.  Abacavir induced hypersensitivity in HIV infected individuals is associated with an increased frequency of Th0 T cells , 2000 .

[30]  E. Caumes,et al.  Hypersensitivity syndrome associated with efavirenz therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Phair,et al.  Clinical experience with non-nucleoside reverse transcriptase inhibitors. , 1997, AIDS.

[32]  H. Satoh,et al.  The immunologic and metabolic basis of drug hypersensitivities. , 1988, Annual review of pharmacology and toxicology.